ODAN-SULFACETAMIDE 10 % — DIN 00622966
SULFACETAMIDE SODIUM : 10 % · ODAN LABORATORIES LTD · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is ODAN-SULFACETAMIDE?
ODAN-SULFACETAMIDE 10 % contains SULFACETAMIDE SODIUM : 10 %. It is listed in the Health Canada Drug Product Database under DIN 00622966, held by ODAN LABORATORIES LTD, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 23-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ODAN-SULFACETAMIDE used for?
Treatment of conjunctivitis and superficial ocular infections due to susceptible microorganisms; adjunctive in systemic sulfonamide therapy of trachoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Sulfacetamide cost around the world?
Sulfacetamide is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Saudi Arabia publishes a public; South Africa publishes a single exit price; United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 8 | 9 | SAR███.██ |
| United States | acquisition | 1 | 1 | USD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
11 pack listings across 10 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Sulfacetamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Sulfacetamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Sulfacetamide, across 13 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAUSCH & LOMB CANADA INC. | 2 | 0 | BALSULPH OPH LIQ 10.0%, BALSULPH OPH ONT 10.0% | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-SULFACETAMIDE SOD OPH SOLN 30%, PMS-SULFACETAMIDE SODIUM LIQ 10% | No marketed DIN |
| SCHERING-PLOUGH CANADA INC | 2 | 0 | SODIUM SULAMYD OPH DPS 30%, SODIUM SULAMYD OPH ONT 10% | No marketed DIN |
| ALCON CANADA INC | 1 | 0 | CETAMIDE ONT 10% | No marketed DIN |
| ALLERGAN INC | 1 | 0 | BLEPH 10 DPS | No marketed DIN |
| ALTIMED PHARMA INC. | 1 | 0 | OPHTHO-SULF LIQ 10% | No marketed DIN |
| LABORATOIRES CHARTON LABORATORIES 17800 Lapointe Mirabel Quebec Canada J7J 1P3 | 1 | 0 | SULFEX 10% | No marketed DIN |
| ODAN LABORATORIES LTD | 1 | 0 | ODAN-SULFACETAMIDE | No marketed DIN |
| PHARMA STULLN INC. | 1 | 0 | SULFACETAMIDE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SODIUM SULAMYD 10% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 % |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | 15 mL plastic dropper bottles. |
| Storage | Store between 2° and 30°C. Keep container tightly closed. Protect from light. Do not use solutions if coloured. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Sulfacetamide |
|---|---|
| ATC code | S01AB04 |
| AHFS class | 52:16.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00622966 |
|---|---|
| DIN (unpadded, as printed on some documents) | 622966 |
| Brand name | ODAN-SULFACETAMIDE |
| Generic / active ingredient | SULFACETAMIDE SODIUM : 10 % |
| Market authorization holder | ODAN LABORATORIES LTD |
| Health Canada schedule | Prescription |
| ATC code | S01AB04 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01AB |
| Current status | DORMANT |
| Status date | 23-Jun-2017 |
| Original market date | 1985-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Conjunctivitis: 1-2 drops every 2-3 hours initially, then tapered. Trachoma: 2 drops every 2 hours as adjunct to systemic therapy. Usual duration 7-10 days.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to sulfonamides or to any ingredient of the preparation.
Warnings and precautions
FOR TOPICAL EYE USE ONLY – NOT FOR INJECTION. Discontinue at first sign of hypersensitivity. Prolonged use may lead to overgrowth of nonsusceptible organisms.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BALSULPH OPH LIQ 10.0% | 100 MG | DROPS | BAUSCH & LOMB CANADA INC. | CANCELLED POST MARKET | 00772313 |
| BALSULPH OPH ONT 10.0% | 10 % | OINTMENT | BAUSCH & LOMB CANADA INC. | CANCELLED POST MARKET | 00790842 |
| BLEPH 10 DPS | 10 % | DROPS | ALLERGAN INC | CANCELLED POST MARKET | 00001287 |
| CETAMIDE ONT 10% | 10 % | OINTMENT | ALCON CANADA INC | CANCELLED POST MARKET | 00252522 |
| OPHTHO-SULF LIQ 10% | 10 % | LIQUID | ALTIMED PHARMA INC. | CANCELLED POST MARKET | 00707465 |
| PMS-SULFACETAMIDE SOD OPH SOLN 30% | 300 MG | DROPS | PHARMASCIENCE INC | CANCELLED POST MARKET | 00762059 |
| PMS-SULFACETAMIDE SODIUM LIQ 10% | 10 % | LIQUID | PHARMASCIENCE INC | CANCELLED POST MARKET | 00838934 |
| SODIUM SULAMYD 10% | 100 MG | DROPS | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 00028053 |
| SODIUM SULAMYD OPH DPS 30% | 300 MG | DROPS | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | 00028061 |
| SODIUM SULAMYD OPH ONT 10% | 10 % | OINTMENT | SCHERING-PLOUGH CANADA INC | CANCELLED POST MARKET | 00028347 |
2 · Same class — other molecules in ATC S01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sulfacetamide | BALSULPH OPH LIQ 10.0% · BALSULPH OPH ONT 10.0% · BLEPH 10 DPS · CETAMIDE ONT 10% · +9 more | 13 | 0 | Not in Canada |
| Sulfacetamide, Combinations | VASOSULF OPH SOLN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01AE | Besifloxacin · Ciprofloxacin · Gatifloxacin · Moxifloxacin · Ofloxacin | 25 | 12 |
| S01AA | Azithromycin · Bacitracin · Chloramphenicol · Chlortetracycline · Combinations Of Different Antibiotics · +6 more | 84 | 9 |
| S01AD | Ganciclovir · Idoxuridine · Trifluridine | 6 | 1 |
| S01AX | Norfloxacin · Sodium Borate | 15 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ODAN-SULFACETAMIDE called?
The same molecule, Sulfacetamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| RIACETAMIDE | Latin | Saudi Arabia |
| Lennon Sulphacetamide Eye Ointment | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.